Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer

Choi, Chel Hun; Lee, Yoo-Young; Song, Taejong; Park, Hwang-Shin; Kim, Min Kyu; Kim, Tae-Joong; Lee, Jeong‐Won; Lee, Je‐Ho; Bae, Duk-Soo; Kim, Byoung-Gie

doi:10.1002/cncr.25710

Cited by 15 publications

(8 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choi et al. [38] demonstrated that belotecan, a newly developed camptothecin analog, showed potent efficacy in combination with carboplatin for recurrent ovarian cancer patients at phase II.…”

Section: Discussionmentioning

confidence: 99%

“…Su and coworkers [37] reported that noscapine, an opium alkaloid, increased cisplatin-induced apoptosis and inhibition of cell proliferation through the inactivation of hypoxia-induced factor 1 alpha (HIF-1a) transcription in C13K ovarian cancer cells. Choi et al [38] demonstrated that belotecan, a newly developed camptothecin analog, showed potent efficacy in combination with carboplatin for recurrent ovarian cancer patients at phase II.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin synergistically enhances cisplatin‐induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK‐OV‐3 cells

Kim¹,

Jeong²,

Kim

et al. 2011

Journal of Pineal Research

View full text Add to dashboard Cite

To evaluate melatonin's ability to enhance ovarian cancer cells to cisplatin treatment for ovarian cancer, this study was performed. Melatonin by itself had no significant cytotoxicity against SK-OV-3 cells, while cisplatin suppressed the cell viability in a dose-dependent manner. Combined treatment with cisplatin and melatonin synergistically inhibited the viability of SK-OV-3 cells with the synergism between two drugs (1 > combination index). In contrast, melatonin revealed the protective effect against cisplatin-induced cytotoxicity in OSEN normal ovarian epithelial cells. Cotreatment with cisplatin and melatonin increased the sub-G1 DNA contents and TdT-mediated dUTP nick end-labeling (TUNEL)-positive cells compared with cisplatin control in SK-OV-3 cells, suggesting that melatonin augments cisplatin-induced apoptosis. Consistently, combined treatment of cisplatin and melatonin increased the cleavage of caspase-3 and poly-(ADP-ribose) polymerase (PARP). Importantly, melatonin synergistically inhibited the phosphorylation of extracellular signal-regulated kinase (ERK) along with dephosphorylation of 90-kDa ribosomal S6 kinase (p90RSK) and heat shock protein 27 (HSP27) induced by cisplatin. Furthermore, melatonin remarkably blocked the expression and colocalization of p90RSK and HSP27 by combination treatment with cisplatin. Taken together, our findings demonstrate that melatonin enhances cisplatin-induced apoptosis via the inactivation of ERK/p90RSK/HSP27 cascade in SK-OV-3 cells as a potent synergist to cisplatin treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Melatonin synergistically enhances cisplatin‐induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK‐OV‐3 cells

Kim¹,

Jeong²,

Kim

et al. 2011

Journal of Pineal Research

View full text Add to dashboard Cite

show abstract

“…BP had better response (66.7%, 14/21) than B (15.4%, 2/13) for platinum‐sensitive disease ( P = 0.004), but it was not superior in terms of progression‐free survival (BP, 6 months; B, 7 months). Both BP and B seemed to be effective and safe regimens for patients with platinum‐sensitive or ‐resistant recurrent ovarian cancer . The combined regimen of belotecan followed by oral etoposide for patients with platinum‐resistant or heavily treated ovarian cancer, fallopian tubal cancer, and primary peritoneal cancer, showed promising activity at dosage of 50 mg of oral etoposide …”

Section: Discussionmentioning

confidence: 99%

“…Both BP and B seemed to be effective and safe regimens for patients with platinum-sensitive or -resistant recurrent ovarian cancer. 4,5 The combined regimen of belotecan followed by oral etoposide for patients with platinum-resistant or heavily treated ovarian cancer, fallopian tubal cancer, and primary peritoneal cancer, showed promising activity at dosage of 50 mg of oral etoposide. 6 Compared to topotecan-based chemotherapy, belotecan-based chemotherapy has shown efficiency with acceptable toxicity in recurrent epithelial ovarian cancer.…”

Section: Discussionmentioning

confidence: 99%

Durable response after just one cycle of belotecan‐based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma

Lee

Min

Seo

et al. 2013

J of Obstet and Gynaecol

View full text Add to dashboard Cite

The efficacy of second-line chemotherapy for relapsed primary peritoneal serous carcinoma has been numerously reported, but reports on durable response after second-line therapy have been rare. We report the case of a 66-year-old woman with relapsed primary peritoneal serous carcinoma who showed durable response after just one cycle of second-line belotecan-based therapy. The response might be a complete pathologic remission. Considering the fact that our patient suffered from neutropenic sepsis during her treatment, we concluded that belotecan-based chemotherapy could be a good option for second-line chemotherapy in some selected patients, so patient selection should be carefully performed due to the toxicity of belotecan.

show abstract

“…Toxicites included neutropenia (28.8%), thrombocytopenia (19.8%) and anemia (14.4%). The addition of carboplatin to belotecan nearly doubled the response rate, while toxicities remained similar [40].…”

Section: Immunomodulatory Thalidomide Analog: Lenalidomidementioning

confidence: 96%

Updates on Anti-Cancer Therapy in Ovarian Cancer

Chase¹

2013

Chemotherapy

View full text Add to dashboard Cite

Phase II trials of the VEGF-Trap agent aflibercept demonstrate its effectiveness in reducing malignant ascites. One randomized, placebo-controlled phase II study enrolled fifty-five women with advanced ovarian cancer and recurrent malignant ascites, and found women receiving aflibercept averaged thirty-one days, until repeat paracentesis, compared to eight days which in the placebo group. Fatal bowel perforations occurred in three patients receiving aflibercept, and only in one placebo group patient, demonstrating a notable clinical risk with VEGF-Trap in patients with advanced ovarian cancer [7]. Another phase II study also found benefit from aflibercept in the reduction of malignant ascites, with a 450% increase in the time to repeat paracentesis, when compared to the baseline interval. This study reports that the safety profile of aflibercept is consistent with that of

show abstract

Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer

Cited by 15 publications

References 38 publications

Melatonin synergistically enhances cisplatin‐induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK‐OV‐3 cells

Melatonin synergistically enhances cisplatin‐induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK‐OV‐3 cells

Durable response after just one cycle of belotecan‐based chemotherapy in a patient with relapsed primary peritoneal serous carcinoma

Updates on Anti-Cancer Therapy in Ovarian Cancer

Contact Info

Product

Resources

About